Endo Files Registration Statement with SEC, Advancing Planned Move to NYSE
MALVERN, Pa., July 12, 2024 /PRNewswire/ — Endo, Inc. (OTCQX: NDOI) (“Endo” or the “Company”), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies, today announced that it has publicly filed a registration statement on Form S-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) to register certain shares of common stock held by current shareholders. Endo is neither issuing nor selling new shares of its common stock in connection with the Registration Statement, and there will be no change to the number of outstanding shares.
Related news for (NDOI)
- Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting
- Endo Completes International Pharmaceuticals Business Divestiture
- Endo Champions Men’s Health Month with Education, Awareness, and Outreach
- Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line with New Concentration
- Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance